In addition, the fractalkine-MetS association was evaluated to determine any potential dependence upon well-established risk factors of MetS, such as central obesity, C-reactive protein (CRP), insulin resistance, and dyslipidemia. The gene discussed is CX3CL1; the disease is Abdominal obesity.